Related Experiment Videos
Risperidone as an adjunct to clozapine therapy in chronic schizophrenics
1Erich Lindemann Mental Health Center, Massachusetts General Hospital, Boston, USA.
The Journal of Clinical Psychiatry
|September 1, 1996
Summary
Adding risperidone to clozapine treatment for schizophrenia showed significant symptom reduction and was well-tolerated in an open trial. This combination therapy may offer a promising approach for managing persistent positive and negative symptoms.
Area of Science:
- Psychiatry
- Pharmacology
Background:
- Treatment-resistant schizophrenia often persists despite hospitalization.
- Patients may continue to experience significant positive or negative symptoms.
Purpose of the Study:
- To evaluate the safety and efficacy of risperidone as an adjunctive therapy for schizophrenia patients already treated with clozapine.
- To assess the impact of adjunctive risperidone on serum clozapine levels.
Main Methods:
- An open-label, 4-week trial involving 12 patients diagnosed with schizophrenia (DSM-III-R).
- Patients received both clozapine and adjunctive risperidone.
- Safety and efficacy were assessed via symptom rating scales and serum drug concentrations.
Main Results:
- Adjunctive risperidone was well-tolerated by patients.
- No significant changes in serum clozapine concentrations were observed.
- Significant reductions in Brief Psychiatric Rating Scale (BPRS) total scores and symptom subscales (positive, negative, depressive) were noted.
- Ten out of 12 participants (83%) achieved at least a 20% reduction in BPRS scores.
Conclusions:
- Combining risperidone with clozapine appears to be a safe and effective strategy for reducing symptoms in treatment-resistant schizophrenia.
- This adjunctive approach shows potential as a clinical option for managing persistent psychiatric symptoms.
- Further validation in controlled trials is recommended to confirm these findings.